Corcept Therapeutics (NASDAQ: CORT) exec exercises and sells 3,700 shares
Rhea-AI Filing Summary
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options to acquire 3,700 shares of common stock at $21.65 per share on August 4, 2026 and sold 3,700 shares at a weighted average price of $113.1248 per share under a Rule 10b5-1 plan adopted on November 27, 2024.
The options exercised were fully exercisable, and 126,300 option shares remained directly held after the transaction. The reported common stock position includes unvested restricted stock awards that each vest 100% on the one-year anniversary of their respective grant dates, subject to specified conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,700 shares ($338K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Guyer William
Role
Chief Development Officer
Sold
3,700 shs ($419K)
Approx. gross sale proceeds
$419K
Approx. exercise cost
$80K
Approx. pre-tax spread
$338K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F4 | 3,700 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 3,700 | $21.65 | $80K |
| Sale | Common Stock F2, F3, F1 | 3,700 | $113.1248 | $419K |
Holdings After Transaction:
Stock Option (right to buy) — 126,300 shares (Direct);
Common Stock — 3,985 shares (Direct)
Footnotes (4)
- F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Fully exercisable.
Key Figures
Shares sold: 3,700 shares
Shares acquired via option exercise: 3,700 shares
Option exercise price: $21.65 per share
+3 more
6 metrics
Shares sold
3,700 shares
Common stock sold on August 4, 2026
Shares acquired via option exercise
3,700 shares
Common shares received from option exercise on August 4, 2026
Option exercise price
$21.65 per share
Stock options exercised for 3,700 shares on August 4, 2026
Weighted average sale price
$113.1248 per share
Common stock sale; individual prices ranged from $112.92 to $113.455 per share
Options remaining after exercise
126,300 shares
Stock options directly held after the reported derivative transaction
10b5-1 plan adoption date
November 27, 2024
Rule 10b5-1 trading plan covering the reported sale
Key Terms
Rule 10b5-1 plan, restricted stock awards, weighted average sale price, Stock Option (right to buy)
4 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock awards financial
"Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Corcept Therapeutics (CORT) report for William Guyer?
Corcept Therapeutics reported that Chief Development Officer William Guyer exercised stock options for 3,700 shares of common stock at $21.65 per share and on the same day sold 3,700 shares at a weighted average price of $113.1248 per share.
What option position does William Guyer retain in Corcept Therapeutics (CORT)?
After exercising options for 3,700 shares, William Guyer directly held 126,300 option shares related to Corcept common stock. The exercised option series was described as fully exercisable, with an exercise price of $21.65 per share and a stated expiration of September 1, 2031.
What are the terms of William Guyer’s restricted stock awards at Corcept (CORT)?
His reported common stock holdings include unvested restricted stock awards: 224 shares from December 1, 2025, 498 shares from March 2, 2026, and 877 shares from June 1, 2026. For each grant, 100% of the shares vest on the one-year anniversary, subject to certain requirements.